Marvel Biosciences announced that its Australian patent application for MB-204, a novel therapeutic candidate for autism and related disorders, has been accepted and is expected to be granted soon. This strengthens their global patent portfolio as MB-204 moves into Phase I clinical trials following positive preclinical results, including superior efficacy in Rett syndrome models. The expanded patent protection enhances the drug's commercial value by extending exclusivity and attracting potential partners. Marvel is also developing pediatric-friendly formulations and has secured funding and partnerships to support its clinical development progress.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
